高脂肪摂取は,抗生物質による腸内微生物群のクロストリディアの枯渇後にソルビトール不耐性を維持する
Jee-Yon Lee1, Connor R Tiffany1, Scott P Mahan1
1Department of Medical Microbiology and Immunology, School of Medicine, University of California at Davis, One Shields Ave, Davis, CA 95616, USA.
Cell
|February 17, 2024
まとめ
抗生物質や高脂肪食は 腸内細菌を破壊し 長期にわたるソルビトール不耐性を引き起こす可能性があります 微生物によるソービトール分解の回復は,特にバチラート生産者によって,潜在的な治療戦略を提供する.
科学分野:
- 微生物学
- 胃腸内科
- 免疫学
背景:
- 炭水化物不耐症は,ソルビトール不耐症を含む,人口の重要な部分に影響します.
- ソルビトール不耐症の根底にある正確なメカニズムは,しばしば吸収不良に関連しており,完全に理解されていません.
研究 の 目的:
- ソルビトール不耐症の原因を解明する
- ソルビトール不耐症の潜在的な治療標的を特定する.
主な方法:
- 抗生物質と高脂肪食によるソルビトール不耐性の誘発
- 微生物のクロストリディアの量とソルビトール分解の評価
- プロバイオティクスのエシェリキア・コーライとバチラート産生のアナエロタイプカカエとの介入
- ペロキシソーム増殖器活性化受容体-ガンマ (PPAR-γ) 信号伝達と上皮低酸素の役割の調査.
主要な成果:
- 抗生物質への曝露と高脂肪食はクロストリディアの豊富性を低下させ,微生物のソルビトール分解を阻害し,マウスのソルビトール不耐性を引き起こした.
- エシェリキア・コライの注射はソービトール分解を部分的に回復させたが,クロストリディアの多量性は回復しなかった.
- Anaerostipes caccaeの予防接種は,プロバイオティクスのクリアランスの後でも,クロストリディアの豊富さを回復し,ソービトール誘発性下痢から保護しました.
- A. caccaeによって生成されるブチラートは,PPAR-γシグナル伝達と上皮低酸素を刺激することで,クロストリディアの豊富さを回復させた.
結論:
- 微生物によるソルビトール分解はソルビトール不耐性の重要な要因です.
- クロストリディアの繁殖と機能の回復は,ブチラートによる可能性があり,有望な治療法です.
- 微生物のソルビトール分解をターゲットにすることで,ソルビトール不耐性を診断し,治療し,予防する可能性があります.
関連する概念動画
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Drugs for Treatment of Constipation-Predominant IBS
164
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
164
Glucose Transporters
22.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.8K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
175
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
175
Irritable Bowel Syndrome I: Introduction
274
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
274
Drugs for Treatment of Diarrhea-Predominant IBS
170
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
170


